Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis
NCT02066519 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45
Last updated 2018-08-13
Summary
The purpose of this study is to demonstrate that a 3 months physical exercise programme improves the Quality of Life of patients with generalized Myasthenia Gravis (MG) stabilized since at least 6 months under prednisone and/or azathioprine.
Conditions
Interventions
- BEHAVIORAL
-
Physical exercise programme using a rowing machine
3 sessions per week of individualized physical training using a rowing machine during 3 months.
Sponsors & Collaborators
-
Assistance Publique - Hôpitaux de Paris
lead OTHER
Principal Investigators
-
Tarek SHARSHAR, MD, PhD · ICU and medical surgery Service, Raymond Poincaré Hospital, 92380 Garches, France
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-10-31
- Primary Completion
- 2018-01-10
- Completion
- 2018-04-06
Countries
- France
Study Locations
More Related Trials
-
Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis
NCT00987116 ·Status: COMPLETED ·Phase: PHASE4
-
The EXPLORE MG Registry for Myasthenia Gravis
NCT03792659 ·Status: RECRUITING
-
Disease-Modifying Treatments for Myasthenia Gravis
NCT03490539 ·Status: COMPLETED
-
Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis
NCT07224386 ·Status: NOT_YET_RECRUITING
-
Clinical Prognosis and Progression of Myasthenia Gravis Patients
NCT04101578 ·Status: UNKNOWN
-
A Study in Patients With Myasthenia Gravis in China
NCT06700616 ·Status: ACTIVE_NOT_RECRUITING
-
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
NCT07039916 ·Status: RECRUITING ·Phase: PHASE3
-
Predictors and Prognostic Factors of Myasthenia Gravis Outcome
NCT05214612 ·Status: RECRUITING
-
The Impact of Myasthenia Gravis in the Real World
NCT04176211 ·Status: COMPLETED
-
Tacrolimus Combined With Low-dose Prednisone for Treatment of Myasthenia Gravis
NCT04768465 ·Status: UNKNOWN
-
An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
NCT03669588 ·Status: COMPLETED ·Phase: PHASE3
-
Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
NCT01828294 ·Status: TERMINATED ·Phase: PHASE1
-
Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis
NCT02565576 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
NCT05067348 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy of Methotrexate in Myasthenia Gravis
NCT00814138 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
NCT03772587 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Vaccination Against COVID-19 in Neuromuscular Patients
NCT05311904 ·Status: COMPLETED
-
A Prospective Cohort Study Of Myasthenia Gravis
NCT04674605 ·Status: UNKNOWN
-
Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment
NCT06381284 ·Status: COMPLETED
-
Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis
NCT03052751 ·Status: COMPLETED ·Phase: PHASE2
-
Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
NCT07247279 ·Status: RECRUITING
-
An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
NCT03896295 ·Status: TERMINATED ·Phase: PHASE2
-
Efgartigimod for Consolidation Therapy in gMG
NCT07079020 ·Status: NOT_YET_RECRUITING
-
Prevalence and Impact of Fatigue in Myasthenic Patients Followed At Clermont-Ferrand University Hospital - "My" Asthenia
NCT06877403 ·Status: ENROLLING_BY_INVITATION